Transactions
3
Insider / Wave Life Sciences, Inc.
BOLNO PAUL
President and CEO at Wave Life Sciences, Inc.
- Company
- Wave Life Sciences, Inc.
- Ticker
- WVE
- First filing on record
- February 11, 2026
- Latest trade on record
- February 9, 2026
- SEC filings
- EDGAR ↗
BOLNO PAUL, President and CEO at Wave Life Sciences, Inc., has disclosed 3 transactions in WVE since February 11, 2026: 0 purchases (0 open-market buys) and 1 sale, worth about $141K at the reported prices. The latest was filed February 11, 2026, 6 days after the trade; 2 filings were late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
1
Avg. disclosure lag
4.7d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months BOLNO PAUL made no purchases and 1 sale worth $141K, plus 2 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
BOLNO PAUL has traded 1 stock on record; the largest by dollars is WVE.
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 2 | 1,165,000 | — |
| S | Open-market sale | 1 | 10,480 | $141K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 3 | 0 | 1 · $141K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| WVE | Other A | February 5, 2026 | February 11, 2026 | 6d | 1,000,000 | — | — | latederivative | Form 4 ↗ | |
| WVE | Sell S | February 9, 2026 | February 11, 2026 | 2d | 10,480 | $13 | $141K | Form 4 ↗ | ||
| WVE | Other A | February 5, 2026 | February 11, 2026 | 6d | 165,000 | — | — | late | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| February 11, 2026 | Form 4 | 0001193125-26-047322 | 3 | published | EDGAR ↗ |
Other insiders at Wave Life Sciences, Inc.
- Francis Chris See Remarks 36 rows
- GLAXOSMITHKLINE PLC Insider 33 rows
- Moran Kyle Chief Financial Officer 19 rows
- Tan Aik Na Director 19 rows
- HENRY CHRISTIAN O Director 12 rows
- Wagner Heidi L Director 10 rows
- RA CAPITAL MANAGEMENT, L.P. Director 7 rows
- Rawcliffe Adrian Director 7 rows
- TAKANASHI KEN Director 5 rows
- CORRIGAN MARK Director 4 rows
Everyone on file, with contracts and lobbying under the company's name: Wave Life Sciences, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 3 | February 11, 2026 | February 11, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.